Raedler, L. A. (2016). Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. Am Health Drug Benefits.
Style de citation ChicagoRaedler, Lisa A. "Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma." Am Health Drug Benefits 2016.
Style de citation MLARaedler, Lisa A. "Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma." Am Health Drug Benefits 2016.
Attention : ces citations peuvent ne pas être correctes à 100%.